ALEXANDRIA, Va., Aug. 12 -- United States Patent no. 12,383,581, issued on Aug. 12, was assigned to The Trustees of the University of Pennsylvania (Philadelphia).

"Compositions and methods for targeting CD13 and TIM-3 with CAR T cells to treat acute myeloid leukemia" was invented by Xianxin Hua (Wynnewood, Pa.), Xin He (Philadelphia) and Xuyao Zhang (Shanghai).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention includes compositions and methods for treating AML utilizing bispecific CARs. In certain aspects, the invention includes a bispecific split CAR which binds CD13 and TIM-3 on AML cells."

The patent was filed on Oct. 9, 2020, under Application No. 17/767,831.

*For further information, ...